Mesothelioma: A Review

Frank Edmund Mott

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Mesothelioma is an insidious disease with long latency after asbestos exposure. New cases are continually diagnosed, although levels are declining with recognition of the asbestos risk and efforts to remove asbestos from the workplace. Treatment for early stage disease with surgery and radiation is potentially curative, but many patients either are too ill to undergo aggressive surgery or present with advanced disease. Chemotherapy with cisplatin and pemetrexed is considered standard, although relapse is common. Second-line therapy is disappointing. New targeted therapies may pose promise and are being addressed in various clinical trial settings. Palliative care remains an important component of the management of this devastating illness.

Original languageEnglish (US)
Pages (from-to)70-79
Number of pages10
JournalOchsner Journal
Volume12
Issue number1
StatePublished - Mar 26 2012

Fingerprint

Asbestos
Mesothelioma
Pemetrexed
Palliative Care
Workplace
Cisplatin
Therapeutics
Clinical Trials
Radiation
Recurrence
Drug Therapy

Keywords

  • Asbestos
  • Diagnosis
  • Malignant pleural mesothelioma
  • Targeted therapies
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mott, F. E. (2012). Mesothelioma: A Review. Ochsner Journal, 12(1), 70-79.

Mesothelioma : A Review. / Mott, Frank Edmund.

In: Ochsner Journal, Vol. 12, No. 1, 26.03.2012, p. 70-79.

Research output: Contribution to journalReview article

Mott, FE 2012, 'Mesothelioma: A Review', Ochsner Journal, vol. 12, no. 1, pp. 70-79.
Mott FE. Mesothelioma: A Review. Ochsner Journal. 2012 Mar 26;12(1):70-79.
Mott, Frank Edmund. / Mesothelioma : A Review. In: Ochsner Journal. 2012 ; Vol. 12, No. 1. pp. 70-79.
@article{3dee0f9376364c9390b149bcf260222b,
title = "Mesothelioma: A Review",
abstract = "Mesothelioma is an insidious disease with long latency after asbestos exposure. New cases are continually diagnosed, although levels are declining with recognition of the asbestos risk and efforts to remove asbestos from the workplace. Treatment for early stage disease with surgery and radiation is potentially curative, but many patients either are too ill to undergo aggressive surgery or present with advanced disease. Chemotherapy with cisplatin and pemetrexed is considered standard, although relapse is common. Second-line therapy is disappointing. New targeted therapies may pose promise and are being addressed in various clinical trial settings. Palliative care remains an important component of the management of this devastating illness.",
keywords = "Asbestos, Diagnosis, Malignant pleural mesothelioma, Targeted therapies, Treatment",
author = "Mott, {Frank Edmund}",
year = "2012",
month = "3",
day = "26",
language = "English (US)",
volume = "12",
pages = "70--79",
journal = "Ochsner Journal",
issn = "1524-5012",
publisher = "Ochsner Clinic",
number = "1",

}

TY - JOUR

T1 - Mesothelioma

T2 - A Review

AU - Mott, Frank Edmund

PY - 2012/3/26

Y1 - 2012/3/26

N2 - Mesothelioma is an insidious disease with long latency after asbestos exposure. New cases are continually diagnosed, although levels are declining with recognition of the asbestos risk and efforts to remove asbestos from the workplace. Treatment for early stage disease with surgery and radiation is potentially curative, but many patients either are too ill to undergo aggressive surgery or present with advanced disease. Chemotherapy with cisplatin and pemetrexed is considered standard, although relapse is common. Second-line therapy is disappointing. New targeted therapies may pose promise and are being addressed in various clinical trial settings. Palliative care remains an important component of the management of this devastating illness.

AB - Mesothelioma is an insidious disease with long latency after asbestos exposure. New cases are continually diagnosed, although levels are declining with recognition of the asbestos risk and efforts to remove asbestos from the workplace. Treatment for early stage disease with surgery and radiation is potentially curative, but many patients either are too ill to undergo aggressive surgery or present with advanced disease. Chemotherapy with cisplatin and pemetrexed is considered standard, although relapse is common. Second-line therapy is disappointing. New targeted therapies may pose promise and are being addressed in various clinical trial settings. Palliative care remains an important component of the management of this devastating illness.

KW - Asbestos

KW - Diagnosis

KW - Malignant pleural mesothelioma

KW - Targeted therapies

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84858663671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858663671&partnerID=8YFLogxK

M3 - Review article

C2 - 22438785

AN - SCOPUS:84858663671

VL - 12

SP - 70

EP - 79

JO - Ochsner Journal

JF - Ochsner Journal

SN - 1524-5012

IS - 1

ER -